In various embodiments, the present disclosure pertains to compositions and methods for prevention or treatment of
cancer, prevention, treatment or inhibition of viral or microbial infection or replication, or prevention, treatment or inhibition of other
disease. In some embodiments, the composition includes at least one of an
arginine mimic (TA-R) or a
histidine mimic (TA-H) or the administration thereof. In some embodiments, the at least one TA-R or TA-H is a TA-R that can include, without limitation, trans-4-guanidinomethylcyclohexanecarboxylic acid (TA-R1), amino((((1r,4r)-4-(methoxycarbonyl)cyclohexyl)methyl)amino)methaniminium
chloride (TA-R1-OMe), amino(((1r,4r)-4-carboxycyclohexyl)amino)methaniminium
chloride (TA-R2), cis-amino(((3-carboxycyclohexyl)methyl)amino)methaniminium
chloride (TA-R3), cis-amino(((3(methoxycarbonyl)cyclohexyl)methyl)amino)methaniminium chloride (TA-R3-OMe), and cis-3-(guanidinomethyl)
cyclopentane-1-
carboxylic acid (TA-R4), compounds that have a
cycloalkane having two or more functional groups off the
cycloalkane, derivates thereof, salts thereof, and combinations thereof.